Neutralization of HIV-1 subtypes: Implications for vaccine formulations

Simple item page
dc.contributor.authorSmith, T.L.
dc.contributor.authorVan Rensburg, E. J.
dc.contributor.authorEngelbrecht, S.
dc.date.accessioned2011-05-15T16:17:03Z
dc.date.available2011-05-15T16:17:03Z
dc.date.issued1998
dc.description.abstractMore than 20.8 million people are infected with HIV in sub-Saharan Africa, with South Africa having one of the fastest growing HIV-1 epidemics, where an estimated 2.4 million people were infected. Thirty-two sera from 25 patients were tested for their ability to neutralize HTLV-III(B) (IIIB) and four primary isolates representing subtypes B, C, D, and a recombinant gag C/env B type. A CEM-SS cell line-based assay was used and the neutralizing titer was defined as the reciprocal of the highest dilution giving a 50% reduction in p24 antigen production. All isolates were neutralized better by subtype-specific sera, except for the C4714 strain, which was neutralized by both subtype B and C sera. C4714 was neutralized by 18/25 (72%) sera, IIIB by 19/32 (59%) sera, D482 by 7/31(23%) sera, B3245 by 6/29 (21%) sera, and the recombinant B/C1491 isolate by 4/25 (16%) sera. Five sera were unable to neutralize any of the isolates. The V3 region of the isolates used in the neutralization assay was amplified by PCR, directly sequenced, and analyzed to reveal variability between the consensus HIV-1 sequences and the isolates. HIV-1 strain C4714 was neutralized more effectively with the sera tested than the IIIIB laboratory strain. Variability in the amino acid sequence of the V3 region, which can alter the conformation of the V3 loop secondary structure, can influence the neutralization of a particular viral isolate. Vaccine formulations should be broadened to include multiple subtypes, especially C subtypes, which is rapidly spreading worldwide.
dc.description.versionArticle
dc.identifier.citationJournal of Medical Virology
dc.identifier.citation56
dc.identifier.citation3
dc.identifier.issn01466615
dc.identifier.other10.1002/(SICI)1096-9071(199811)56:3<264::AID-JMV15>3.0.CO;2-E
dc.identifier.urihttp://hdl.handle.net/10019.1/14051
dc.subjectgag protein
dc.subjecthuman immunodeficiency virus vaccine
dc.subjectneutralizing antibody
dc.subjectvirus envelope protein
dc.subjectamino acid sequence
dc.subjectantibody titer
dc.subjectarticle
dc.subjectclinical article
dc.subjectcontrolled study
dc.subjecthuman
dc.subjecthuman cell
dc.subjecthuman immunodeficiency virus 1
dc.subjecthuman immunodeficiency virus infection
dc.subjectpolymerase chain reaction
dc.subjectsouth africa
dc.subjectvaccine production
dc.subjectvirus isolation
dc.subjectvirus neutralization
dc.subjectvirus typing
dc.subjectAIDS Vaccines
dc.subjectAmino Acid Sequence
dc.subjectCell Line
dc.subjectCells, Cultured
dc.subjectHIV Antibodies
dc.subjectHIV Core Protein p24
dc.subjectHIV Envelope Protein gp120
dc.subjectHIV Infections
dc.subjectHIV-1
dc.subjectHumans
dc.subjectMolecular Sequence Data
dc.subjectNeutralization Tests
dc.subjectPeptide Fragments
dc.subjectPolymerase Chain Reaction
dc.subjectHTLV
dc.subjectHuman immunodeficiency virus
dc.subjectHuman immunodeficiency virus 1
dc.subjectRNA viruses
dc.titleNeutralization of HIV-1 subtypes: Implications for vaccine formulations
dc.typeArticle
Files
Collections
Stellenbosch University - Scopus Tygerberg Hospital Publications